Beat and held: IOL's pivot from ibuprofen commodity to diversified API platform
Q1 revenue surged 37% and EBITDA margin beat guidance at 14.6%, yet management held full-year guidance—a disciplined choice that reveals the real story: non-ibuprofen APIs now 43% of pharma revenue and growing 67% YoY, capacity-driven operating leverage is moving margins, and the street is quietly loading the position.
IOL Chemicals delivered a headline beat but the real story is what management held steady. Revenue of ₹756.3 Cr jumped 37% YoY and EBITDA margin of 14.6% beat the guided 14-14.5% for FY27. Yet management did not upgrade full-year guidance; instead, it held FY27 targets and introduced new FY28 guidance at 15-17% EBITDA margin. This is not caution born of weakness—it is disciplined guidance calibration on the back of a genuine business remix. Non-ibuprofen APIs have shifted from 36% to 43% of pharma revenue in a single year and are growing 67% YoY. Capacity-driven operating leverage is moving the margin needle. Export markets (28.5% of revenue, up 410 bps YoY) are expanding into regulated geographies. This quarter is a pivot point: the company is remaking itself from a single-product commodity player into a diversified API platform with regulated market traction.
₹756.3 Cr
+37.1% YoY | +22.1% QoQ
14.6%
vs FY27 guidance 14-14.5% | +220 bps YoY
₹64.4 Cr
+89.8% YoY | organic, no one-offs
43%
of pharma revenue | +67% YoY | tracking to 50% by FY29
28.5%
of total revenue | +410 bps YoY | NMPA China approval for clopidogrel
80–95%
most assets maxed | paracetamol 55%, targeting 70%
The Tension: Beat But Didn't Raise
Q1 delivered a 14.6% EBITDA margin against a guided 14-14.5% for the full year. Management had room to raise guidance, yet held FY27 targets at 15-20% revenue growth and 14-15% EBITDA margin. This is not a red flag—it is a calculated choice. On the call, management explicitly stated 'we prefer being correct over over-promising,' and the strategy is sound: confirm 1/4 of the year at a beat and lock in credibility for the remaining 9 months, rather than front-load optimism and risk a miss in Q3-Q4. However, it signals one thing clearly: management is hedging on full-year visibility. The cited pressures are real: geopolitical uncertainty, input cost inflation (ethyl acetate and acetic anhydride spiked post-US-Iran tensions in March), and customer agreement volatility on the export side. The refusal to raise despite a beat is professional risk discipline, not a harbinger of weakness ahead.
What Changed on This Call
Non-ibu pharma jumped from 36% to 43% of revenue YoY; +67% growth
EBITDA margin guidance raised from 14-14.5% to 14-15% for FY27
FY28 guidance introduced: 15-20% revenue, 15-17% EBITDA margin (vs FY27: 14-15%)
Export mix surged 410 bps YoY to 28.5%; NMPA China approval for clopidogrel confirmed
Paracetamol capacity ramp: tripled to 10,800 MTPA, now 55% utilization, targeting 70% by FY27 end
Triacetin facility (6,000 MTPA) began production May 2026; targeting ₹120 Cr revenue at steady state
Earnings Quality: Operating Leverage, No One-Time Gains
Management explicitly refuted analyst questions on inventory gain impact: Q4 FY26 benefited from 10-15 days of inventory valuation gain from price appreciation during that quarter, but Q1 had none. The 89.8% PAT growth is entirely organic—driven by capacity utilization (80-95% on most assets except paracetamol), improved product mix (non-ibu portfolio +67% YoY), operational efficiencies, and stronger export realization. Gross margin compressed sequentially due to input cost lag: ethyl acetate and acetic anhydride prices spiked in March; customer price pass-through typically lags by 1–2 months. By Q1, management expected this gap to stabilize. The quality of earnings here is high: operating leverage from existing capacity and mix is moving the needle, not fair-value adjustments or exceptional items. This is sustainable profit, not a pop.
Non-ibu products grew 67% YoY
SupportedNon-ibu pharma revenue now 43% of total (36% prior year); broad-based growth in paracetamol, clopidogrel, pantoprazole
EBITDA margin 14.6% beats 14-14.5% guidance
SupportedEBITDA ₹111 Cr on ₹756 Cr revenue = 14.6%; beat on first call post-results
PAT growth is operating leverage, not inventory gains
SupportedPAT ₹64.4 Cr (+89.8% YoY) driven by capacity utilization, product mix, efficiency; no inventory gain in Q1
Export at 28.5%, tracking to 25-30% FY27 target
SupportedExport revenue ₹215 Cr (28.5% of ₹756 Cr) vs ₹164 Cr prior year (24.4%); 410 bps YoY gain
Most assets at 80-95% capacity except paracetamol at 55%
SupportedParacetamol 10,800 MTPA capacity, targeting 70% utilization by FY27 end; other assets bottlenecked
Input cost pass-through lag now exhausted
SupportedGross margin compressed QoQ due to Q4 inventory gain (10-15 days) and Q1 cost absorption; management expects no major future variation
The Portfolio Pivot: Non-Ibu Is Now the Growth Engine
The ibuprofen era is not ending, but it is no longer the only story. Non-ibuprofen APIs—paracetamol, clopidogrel, pantoprazole, metformin, fenofibrate—have jumped from 36% of pharma revenue to 43% YoY and grew 67% in a single quarter. Management is targeting 50-55% by FY29. This is not a niche shift; it is a fundamental remix of the revenue base. Paracetamol capacity was tripled from 3,600 MTPA to 10,800 MTPA over two years and is now at 55% utilization, ramping toward 70% by FY27 end. Clopidogrel gained NMPA approval in China, unlocking regulated market access. Pantoprazole is gaining traction domestically and in exports. The capex discipline is evident: management is expanding capacity only where demand signals justify. Greenfield projects (101-acre site in Punjab) are held pending proof-of-concept readiness. This is not speculative capacity inflation; it is demand-led growth backed by actual order flow and customer commitments.
Export Surge and Regulated Market Traction
Exports jumped 410 basis points YoY to 28.5% of total revenue and are tracking to the 25-30% FY27 guidance. The shift is into regulated markets: the company has 5 US FDA approvals on formulator ANDAs, with 2-3 more in pipeline. China NMPA approval for clopidogrel signals regulatory credibility expansion beyond the domestic market. This is significant because regulated market APIs command better realizations and create stickier customer relationships compared to commodity domestic sales. Management acknowledged export customer agreement volatility (agreed quantities can swing quarter-to-quarter), and this is why the guidance is a range rather than a point—honest risk calibration. The export mix is high-quality revenue, not opportunistic spot sales.
How the Street Is Positioned (Post-Result Flows & Price Action)
FII flows were bullish into the quarter. Foreign institutional ownership jumped from 1.72% in Q4 FY26 to 4.87% in Q1 FY27—a gain of 3.15 percentage points. Promoter stake also increased from 57.48% to 62.28% (+4.8 pp), indicating insider confidence and capital deployment. The post-announcement price action, however, was measured: down 0.32% on day 1 (delivery 65.7%, suggesting solid institutional commitment), up 0.83% by day 3, then down 2.05% by day 5. The fading suggests the market initially took the beat at face value, then re-priced on the guidance hold and realized the upside was already partially embedded in the stock (the company is up 143.71% off its 52-week low, trades above the 20-day, 50-day, and 200-day moving averages; RSI at 65.9 signals neutral momentum, not overbought). Current price of ₹163.75 sits 8.83% below the all-time high, leaving room but no collapse signal.
Ranked Risks
Paracetamol utilization ramp execution
MediumCapacity was tripled to 10,800 MTPA; now at 55% utilization, targeting 70% by FY27 end. Paracetamol has historically weak demand; execution risk on both achieving ramp-up and sustaining volume growth. If utilization stalls at 55-60%, the capex becomes a drag on returns and the non-ibu thesis loses its largest driver.
Input cost pass-through lag and inflation
MediumEthyl acetate and acetic anhydride prices spiked post-US-Iran tension in March 2026. Q1 absorbed lag before customer price increases took effect; gross margin compressed QoQ. Management says gap is now exhausted, but future geopolitical shocks (Taiwan tensions, Middle East escalation) could re-open pricing lags and test margins again.
Export customer concentration and volatility
Medium28.5% export mix is high; customers have agreed quantities and can vary Q-to-Q offtakes materially based on their own demand. A major customer reducing orders could create lumpy revenue swings. Management acknowledged this volatility, which is why guidance is a range, but concentration risk remains real.
Greenfield project delays and new platform timing
Low–Medium101-acre site statutory permissions are ongoing; no major project expected in FY27. CMO and backward integration initiatives (KSM opportunities) are at R&D proof-of-concept stage. If delayed, new platform growth stalls and the company relies solely on existing asset productivity for margin gains.
Metformin DCDA sourcing from China
LowMetformin (a non-ibu growth driver) depends on DCDA raw material sourcing from China. Geopolitical tension or tariffs could disrupt supply or inflate costs. Most Indian API players face same constraint, so it is an industry-wide risk, but concentration of supply in one geography is a structural headwind.
The Debate
What to Watch Next
1 · Paracetamol utilization progression and demand signaling
Q2–Q4 must show utilization moving from 55% toward the 70% target by year-end. Quarterly updates on this metric are critical; it is the single largest execution risk for validating the 15-20% revenue growth target and sustaining EBITDA margin above 14%.
2 · EBITDA margin sustainability at 14%+
Q1 delivered 14.6%, but management expects 14-15% for the full year. Input cost environment (ethyl acetate, acetic anhydride pricing) will test pricing power going forward. Watch for any gross margin compression in Q2-Q3; if it persists, the cost pass-through assumption breaks down.
3 · FDA and NMPA approval flow and timing
Management guided 2-3 more US FDA approvals on formulator ANDAs in pipeline, and Triacetin NMPA approval expected in Q3 2026 (3 quarters from May start). Actual approval dates and volume ramp from new products unlock new revenue streams; track this closely.
4 · Export mix stability and customer agreement flow
28.5% export is high and prone to Q-to-Q volatility due to customer agreement quantities. Watch for stability or further gains toward the 30% guidance; any sustained dip below 25% would signal loss of a major customer or order cuts.
5 · Non-ibu portfolio share progression toward 50% by FY29
Now at 43% of pharma revenue; each quarter should show incremental share gains as paracetamol, clopidogrel, and pantoprazole scale. If non-ibu stalls or shrinks as a % of pharma, the diversification narrative derails and the stock reprices lower.
The Honest Read
IOL is not having an exceptional quarter—it is executing a transformation. Revenue growth of 37% YoY is ahead of its mid-to-high teens target, but management held guidance rather than raising it. This is not weakness; it is calibration born of execution discipline and honest risk management. The real story is the portfolio: non-ibuprofen APIs have jumped from 36% to 43% of pharma revenue in one year, growing 67% YoY, and capacity-driven operating leverage is moving EBITDA margins toward 15%. Paracetamol is the lynchpin—if the ramp from 55% to 70% utilization holds, and non-ibu reaches 50% of pharma by FY29, the company shifts from a single-product merchant to a diversified integrated API platform with regulated market traction. If paracetamol execution falters, it is capex drag and margin pressure.
The street is positioning for the upside: FII bought 3.15 pp QoQ, promoters added 4.8 pp, and institutional ownership is now 4.87%. The post-result price action faded (up day 3, then down day 5), which is healthy—it means the beat is already priced and the market is now waiting for Q2–Q4 execution to confirm the thesis. Management's refusal to raise guidance despite a beat is not a red flag; it is professional risk discipline. Watch three things: paracetamol utilization progression, EBITDA margin hold at 14%+, and non-ibu share moving toward 50%. That is the debate resolved over the next 9 months.
The single number to track: EBITDA margin. As long as it stays above 14% and moves toward 15% by FY27 end, the thesis holds and the 2-3 year margin uplift story toward 15-17% becomes credible. If it compresses below 13.5%, the capacity-driven operating leverage narrative breaks and the quarter becomes an outlier, not a structural shift.
Strong execution beats guidance; diversification gaining momentum
The verdict, the claims that held up, the sharpest analyst exchanges, and the risks — the earnings call, decoded from the transcript.
Buy
confidence 7/10
Grade B
Beat FY27 margin guidance (14.6% vs 14-14.5%); first call post-results. Diversification narrative proving out in numbers (non-ibu +67% YoY).
Optimistic
next 1–2 quarters
Optimistic
multi-year
Strong execution on diversification (non-ibu 67% growth) and capacity utilization driven margin expansion to 14.6%, beating 14-14.5% guidance. Revenue +37% YoY and PAT +89.8% reflect operational leverage and improved mix. Risk: execution on FY29 50-55% non-ibu target and capacity ramp sustainability; cost inflation lag on pricing pass-through.
₹756.3 Cr
Revenue · +37.1% YoY₹64.4 Cr
Reported PAT · +89.8% YoYExpanding
Margins · vs guidance: CorroboratedDid the claims hold up?
Non-ibu products grew 67% YoY
METNon-ibu pharma revenue 43% of total (36% prior year), driving portfolio diversification
EBITDA margin 14.6% for Q1
METDelivered 14.6% vs guided 14-14.5% range for FY27; beats guidance
PAT growth driven by operating leverage, not one-off inventory gains
METManagement directly refuted inventory gain; PAT +89.9% reflects capacity utilization, product mix, and export realization
Export contribution 28.5% vs 24.4% YoY
METConfirmed; on track with 25-30% FY27 guidance
Most assets at 80-95% capacity utilization except paracetamol at 55%
METParacetamol expanding from 3,600 MTPA to 10,800 MTPA over 2 years; targeting 70% utilization by FY27 end
Earnings quality
What changed since the last call
Non-ibu portfolio share jumped
Upgrade36% → 43% of pharma revenue YoY; +67% growth driven by paracetamol ramp (10,800 MTPA capacity vs 3,600 prior) and clopidogrel/pantoprazole traction
FY27 EBITDA margin guidance raised
UpgradePrior: 14-14.5%; New: 14-15%. Q1 delivered 14.6%, demonstrating operating leverage and mix benefit execution.
FY28 guidance introduced
UpgradeNew: revenue 15-20%, EBITDA 15-17% (vs FY27: 14-15%). Signals confidence in margin trajectory continuation.
Export contribution accelerated
Upgrade24.4% → 28.5% YoY; new NMPA approval for clopidogrel in China expands regulated market footprint.
Guidance maintained, not upgraded
NeutralDespite Q1 beat, management held FY27 full-year guidance (15-20% revenue, 14-15% margin). Conservative stance to de-risk over-promise.
The Q&A
Analysts pressed hard on volume vs. pricing split (not detailed by mgmt), inventory gain impact (firmly refuted), and gross margin QoQ decline (explained as Q4 inventory benefit + Q1 cost lag). Management held firm, declined competitor commentary. Tone professional but defensive on forward visibility.
Paracetamol demand outlook — Abu Rafe, Wealth Catalyst
AnsweredStarted 2 years ago at 3,600 MTPA, tripled to 10,800 MTPA; now at 55% utilization targeting 70% by FY27 end. Demand growing, IOL gaining position domestically and in exports.
Raw material pricing stability — Abu Rafe, Wealth Catalyst
AnsweredPrices spiked in March, now stable. Delta between raw material and finished product expected to remain constant going forward.
Export mix trajectory — Pahel Sharma, DD Capital
AnsweredTargeting 25-30% range for FY27, hopeful to achieve it. Range accounts for customer agreement volatility.
EBITDA margin drivers at 14.6% — Pahel Sharma, DD Capital
AnsweredHigher capacity utilization, better product mix, operational efficiencies, stronger non-ibu demand, improvements in finished product prices. All factors contributed.
Pharma growth decomposition — Vignesh, Sequent Scientific
PartialMajority from volume increase in pharma products; capacity utilization (80-95% most assets) is key driver. Do not share detailed volume/price split.
Inventory gain quantification — Jainam Ghelani, Svan Investments
AnsweredLittle bit inventory gain in Q4 last 10-15 days, none in Q1. Not correct to allocate profit to inventory gain; driven by capacity, mix, efficiency, non-ibu growth.
Non-ibu portfolio mix shift impact — Surabhi Sutaria, NV Alpha
Partial21-20% from export (mix of regulated and non-regulated); majority is regulated. Achieved 43% overall pharma from non-ibu, targeting 50% near-term.
EBITDA margin sustainability — Soumya, Nirva Securities
AnsweredPrimarily operational efficiencies of existing products with capacity utilization; no major mix change except export penetration. EBITDA is internal efficiencies, not external factors.
Demand visibility and growth sustainability — Maulik Varia, 360 ONE Mutual Fund
AnsweredHigher volumes and better pricing on established products plus new product growth. Reasonable visibility into Q2 order book. Expect 20% revenue, 14-15% EBITDA sustainable for whole year.
Gross margin QoQ decline explanation — Maulik Varia, 360 ONE Mutual Fund
AnsweredYes. Q4 had inventory benefit (10-15 days); Q1 has input price increases, finished prices also up but lag on passing to customers. Price gaps now exhausted; no major future variation.
Non-ibuprofen drivers and forward outlook — Maulik Varia, 360 ONE Mutual Fund
AnsweredParacetamol turnover contributed mainly; clopidogrel and pantoprazole also contributed. Overall, broad-based growth expected.
Regulated market export approvals — Maulik Varia, 360 ONE Mutual Fund
AnsweredAll products have CEP approval; 5 products approved by US FDA, 2-3 more in pipeline (formulator ANDAs filed). NMPA China approved clopidogrel. Targeting different regulated markets by customer need.
Ibuprofen portfolio share evolution — Nimish Verma, AAS Capital
AnsweredIbuprofen is one of best products; replicating leadership model to other products. Broad-based growth across all products as they reach scalability. Will move toward diversified API platform.
Backward integration KSM opportunities — Nimish Verma, AAS Capital
PartialWorking on different R&D streams; will provide update once POC ready with proof-of-concept.
Greenfield site timeline — Nimish Verma, AAS Capital
AnsweredStatutory permissions underway; R&D working on product mix. Will start work once POC ready. Probably not in this FY.
Chemical segment EBITDA peak — Sheikh Mohammed, Individual Investor
AnsweredEBITDA margin on upward trend this quarter. Increased capacities for ethyl acetate and acetic anhydride; increased exports contributed. Expect performance to continue.
CMO opportunity assessment — Sheikh Mohammed, Individual Investor
PartialWorking on that segment; will update once POC is ready.
FY27 guidance outperformance potential — Sheikh Mohammed, Individual Investor
AnsweredGuidance was for whole year. With current scenario, may cross that number but not upgrading guidance. Philosophy is to be correct rather than over-promise.
Export guidance defensiveness — Sheikh Mohammed, Individual Investor
AnsweredIf we say 30% it can be 28% or 35%; we prefer being correct over over-promising. Around 30% is mean; hope to achieve or cross it. Export customer agreement variability drives Q-to-Q volatility.
Triacetin facility utilization and economics — Abhishek Kamdar, Value Plus Advisors
AnsweredOnly 1 month of production in Q1; capacity will increase gradually as market penetration builds. Revenue potential ~₹120 Cr per year at steady state.
Triacetin input materials and integration — Abhishek Kamdar, Value Plus Advisors
AnsweredNo, inputs are acetic acid and glycerol; acetic anhydride not used. Cannot compare EBITDA to ethyl acetate due to different usage.
Metformin backward integration — Santosh Shetty, LSG Capital
AnsweredMetformin not backward integrated; depends on DCDA raw material from China. Most companies also source from China; geographically available there.
Export mix drivers — Santosh Shetty, LSG Capital
AnsweredMix of everything: better product mix, operational efficiency, better realization, customer reach. Not dominantly one reason.
Guidance
FY27: +15-20% growth from FY26 base (implied ₹2,600-2,700 Cr full-year guidance)
HighBased on capacity utilization, product mix, operational efficiencies; reasonable order book visibility into Q2
FY28: +15-20% growth (new guidance introduced this call)
MediumContingent on current scenario; management hedged on 6-month view changes
FY27 EBITDA margin: 14-15% (raised from prior 14-14.5%)
HighQ1 delivered 14.6%; margin expansion driven by capacity utilization and non-ibu 67% growth
FY28 EBITDA margin: 15-17% (new, implies further expansion)
MediumBased on continued capacity ramp and non-ibu scale-up; scenario-dependent per management
Annual capex ₹200 Cr (60% expansion, 40% maintenance)
HighConsistent capex run-rate past 4-5 years. Greenfield 101-acre site preparation underway; major project likely FY28+
Risks the call surfaced
Operational execution
MediumParacetamol utilization only 55%, targeting 70% by FY27 end. Historical weak demand and market ramp risk; other APIs also scaling simultaneously.
Cost inflation
MediumEthyl acetate and acetic anhydride prices surged in March 2026 post-US-Iran war. Q1 absorbed lag before customers accepted price increases; gross margin compressed QoQ.
Market concentration
MediumExport business (28.5% of revenue) has customer agreements for fixed quantities; when customers take low quantities in a quarter, export % can dip materially.
Geopolitical & supply chain
MediumMetformin depends on DCDA sourcing from China; ethyl acetate and acetic anhydride subject to geopolitical shocks (US-Iran war). Supply chain uncertainty globally.
Strategic execution
Low101-acre greenfield site statutory permissions ongoing; no major project expected in FY27. CMO and backward integration initiatives at R&D POC stage with uncertain timelines.
Management
Score 7/10. Clear on strategy and diversification narrative; transparent on inventory gains and input cost pressures. Deliberate in guidance calibration ('need to be correct'). Some evasion on competitive positioning and product mix detail. Strong Q1 beat on guidance (14.6% margin vs 14-14.5%; 37% revenue vs mid-to-high teens). Non-ibu portfolio on track (43% vs 36% prior, targeting 50% by FY29). Capacity utilization improving. Track record appears solid but only first call post-results.
1 · Q4 FY27
Paracetamol capacity utilization reaches 70% target
2 · FY28 start
New FDA approvals for 2-3 formulator ANDAs once filed
3 · Sep 2026
Triacetin regulatory approval expected (2-3 quarters from May start)
Risk: execution on FY29 50-55% non-ibu target and capacity ramp sustainability; cost inflation lag on pricing pass-through.
IOL Chemicals: consolidated PAT surges 90% YoY to ₹64.4 Cr as revenue jumps 37%, OPM expands
PAT +89.8% YoY · revenue +37.1% · margins expanding
₹756.26 Cr
+37.1% YoY
₹64.4 Cr
+89.8% YoY
8.42%
+2.3pp YoY
₹2.19
IOL Chemicals and Pharmaceuticals reported consolidated revenue of ₹756.26 Cr for Q1 FY27, up 37.1% YoY from ₹551.69 Cr and 22.1% QoQ from ₹619.45 Cr. Consolidated PAT came in at ₹64.40 Cr, up 89.8% YoY from ₹33.93 Cr and 21.1% QoQ from ₹53.16 Cr, with EPS at ₹2.19 versus ₹1.16 a year ago. There were no exceptional items in the current or comparison quarters, so the growth is entirely operating in nature — unlike FY26's full-year print, which carried an ₹11.21 Cr one-off charge.
Q1 FY-2027 vs prior quarters
Operating margin expanded to 13.69% from 11.26% a year earlier (+243 bps YoY), though it eased from 14.93% in Q4 FY26 (-124 bps QoQ). Net margin followed the same pattern: 8.52% versus 6.07% YoY, and roughly flat against 8.56% in Q4. By segment, Pharmaceuticals remained the larger profit contributor (revenue ₹469.49 Cr, segment PBIT ₹68.81 Cr), but Chemicals did the heavy lifting on margin recovery — segment PBIT nearly tripled YoY to ₹17.32 Cr from ₹5.91 Cr on revenue of ₹364.96 Cr, lifting the segment's PBIT margin to 4.7% from 2.1%.
The stock went into the print at ₹172.96, up 1.1% over the past month of trading.
For context: this is the highest quarterly PAT in the last 6 quarters on our records; revenue is at a 6-quarter high.
Management provided a confident outlook for sustained growth, targeting mid-to-high teens revenue growth annually and an improvement in EBITDA margins to 14%-14.5% for FY27. They are also investing in capacity expansion and operational improvements, with a significant greenfield project expected to take shape over the
— This quarter: beat
The 37% YoY revenue growth runs well ahead of the "mid-to-high teens" annual pace management guided on the Q4 FY26 call (22 May 2026), and the 13.69% OPM is closing in on, but still short of, the 14–14.5% FY27 margin band the company targeted then. No Q1-specific street estimate could be located; the closest available read (Univest) pegs FY27 full-year consensus PAT growth at 12–18% — Q1's +90% YoY pace runs well ahead of that trajectory, though a single quarter isn't directly comparable to a full-year estimate. Standalone and consolidated numbers tell nearly identical stories this quarter (PAT ₹64.48 Cr vs ₹64.40 Cr, a 0.12% gap), the difference owing entirely to the first-time, auditor-flagged-immaterial consolidation of UK subsidiary IOL Pharmaxis, which began operations in April 2026.
W1
OPM trajectory toward management's 14-14.5% FY27 target band — currently at 13.69%, needs further expansion
W2
Chemical segment margin recovery sustainability — PBIT margin rose to 4.7% from 2.1% YoY; watch through H2 FY27 alongside the guided ₹1,200-1,400 Cr greenfield capex
W3
Non-Ibuprofen portfolio mix shift, per management's stated FY27 strategy — no disclosed number this quarter, watch for concall commentary